Serina Therapeutics (SER) Accounts Payables (2017 - 2026)

Serina Therapeutics has disclosed Accounts Payables across 10 years of filings, most recently posting $1.9 million for Q2 2026.

• In Q2 2026, Accounts Payables rose 8.91% year-over-year to $1.9 million; the TTM figure through Jun 2026 stood at $1.9 million (up 8.91% YoY), while the FY2025 annual figure was $1.9 million, up 159.54% from the prior year.
• Accounts Payables came in at $1.9 million for Q2 2026 at Serina Therapeutics, down from $1.9 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $4.0 million in Q1 2024 to a low of $580000.0 in Q4 2023.
• Average Accounts Payables over 5 years is $1.5 million, with a median of $1.3 million recorded in 2023.
• Year-over-year, Accounts Payables jumped 217.99% in 2024 and plunged 70.4% in 2025.
• Over 5 years, Accounts Payables stood at $1.0 million in 2022, then sank by 43.91% to $580000.0 in 2023, then increased by 28.28% to $744000.0 in 2024, then jumped by 159.54% to $1.9 million in 2025, then retreated by 3.78% to $1.9 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $1.9 million in Q2 2026, $1.9 million in Q4 2025, and $2.7 million in Q3 2025.